Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Mai Onishi"'
Autor:
Yuichiro Saizen, Kasumi Ikuta, Mizuki Katsuhisa, Yuko Takeshita, Yuki Moriki, Misaki Kasamatsu, Mai Onishi, Kiyoko Wada, Chiharu Honda, Kyoko Nishimoto, Yoshiko Nabetani, Tomoyuki Iwasaki, Eriko Koujiya, Miyae Yamakawa, Yasushi Takeya
Publikováno v:
American Heart Journal Plus, Vol 38, Iss , Pp 100361- (2024)
Background: The number of patients with multimorbidity has increased due to the aging of the global population. Although the World Health Organization has indicated that multimorbidity will be a major medical problem in the future, the appropriate in
Externí odkaz:
https://doaj.org/article/29ab05ead15649098672d32c8f8f19e7
Autor:
MIN HAN, SHIGEO YAMAGUCHI, MAI ONISHI, TOMOAKI FUJII, MASAKI HOSOYA, XUAN WEN, HIDENORI KIDO, SHUNSUKE KATO
Publikováno v:
Anticancer Research. 42:2277-2288
Autor:
Meiko Nishimura, Takahiro Kogawa, Yuko Akaishi, Misato Ogata, Jun Masuda, Mitsuo Terada, Hitomi Sakai, Kazuki Nozawa, Sasagu Kurozumi, Takamichi Yokoe, Yukinori Ozaki Ozaki, Shu Yazaki, Mai Onishi, Tsutomu Iwasa, Takuma Onoe, Yuta Okumura, Sayaka Nakayama, Kanako Hagio, Yuko Takahashi, Hirokazu Tanino, Junji Tsurutani, Koji Matsumoto, Mototsugu Shimokawa, Toshimi Takano
Publikováno v:
Cancer Research. 82:OT2-19
Background: Abemaciclib is a drug approved for ER-positive and HER2-negative metastatic or recurrent breast cancer and those treatable in an early setting. Some patients with ER-positive and HER2-negative breast cancer pretreated with abemaciclib and
Autor:
Manabu Futamura, Yukinori Ozaki, Mai Onishi, Tsutomu Iwasa, Tetsuyo Maeda, Meiko Nishimura, Mototsugu Shimokawa, Mitsuo Terada, Yuko Tsuboguchi, Kazuki Nozawa, Takamichi Yokoe, Jun Masuda, Hirotsugu Isaka, Yuta Okumura, Misato Ogata, Shu Yazaki, Michiko Kurikawa, Hitomi Sakai, Takuma Onoe, Sayuka Nakayama, Akihiko Shimomura, Akihiro Fujimoto, Toshimi Takano, Kanako Hagio, Sasagu Kurozumi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are
Autor:
Mai Onishi, Shigeo Yamaguchi, Xuan Wen, Min Han, Hidenori Kido, Tomoyuki Aruga, Shin-ichiro Horiguchi, Shunsuke Kato
Purpose Triple-negative breast cancer (TNBC) is considered a heterogeneous population and achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is an only prognostic factor. Previously, the TP53 signature (TP53sig)-score,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f654fb987de03515491b5fea2267fda6
https://doi.org/10.21203/rs.3.rs-1233460/v1
https://doi.org/10.21203/rs.3.rs-1233460/v1
Autor:
Min, Han, Shigeo, Yamaguchi, Mai, Onishi, Tomoaki, Fujii, Masaki, Hosoya, Xuan, Wen, Hidenori, Kido, Shunsuke, Kato
Publikováno v:
Anticancer research. 42(5)
The TP53-signature is a multi-gene signature that can predict TP53 structural mutations. It has presented remarkable ability to predict the prognosis of early-stage breast cancer. However, some samples presented discordance with the signature status
Autor:
Chika Honda, Mai Onishi, Mikio Watanabe, Yoshinori Iwatani, Toshihiko Araki, Yoshiyuki Watanabe, Shiro Yorifuji, Takufumi Yanagisawa, Kazuo Hayakawa, Soshiro Ogata, Masayuki Hirata
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Scientific Reports
Scientific Reports
Brain activity relating to recognition of action varies among subjects. These differences have been hypothesised to originate from genetic and environmental factors although the extent of their effect remains unclear. Effects of these factors on brai
Autor:
Naoko, Iwamoto, Tomoyuki, Aruga, Hiromi, Miyamoto, Chiaki, Saita, Mai, Onishi, Risa, Goto, Toshiyuki, Ishiba, Yayoi, Honda, Katsumasa, Kuroi
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 46(7)
We aimed to examine palbociclib toxicity in patients aged 70 years and older with metastatic breast cancer(MBC). From December 2017 to August 2018, 32 patients with estrogen receptor(ER)-positive, human epidermal growth factor receptor 2(HER2)-negati
Autor:
Yuko Tsuboguchi, Mototsugu Shimokawa, Tsutomu Iwasa, Tetsuyo Maeda, Hitomi Sakai, Takuma Onoe, Shu Yazaki, Misato Ogata, Sayuka Nakayama, Michiko Kurikawa, Mai Onishi, Jun Masuda, Sasagu Kurozumi, Akihiro Fujimoto, Yukinori Ozaki, Toshimi Takano, Mitsuo Terada, Takamichi Yokoe, Meiko Nishimura, Kazuki Nozawa
Publikováno v:
Journal of Clinical Oncology. 38:e13019-e13019
e13019 Background: Since trastuzumab emtansine (T-DM1) was established as a standard treatment option, the treatment strategy of metastatic HER2-positive breast cancer has markedly changed. However, clinical evidence regarding the treatments beyond T
Publikováno v:
JOURNAL OF RURAL PLANNING ASSOCIATION. 32:191-196